塞帕拉比获批在欧洲用于卵巢癌
Sepalna approved in Europe for ovarian cancer
塞帕拉比获批在欧洲作为一线铂类化疗后响应的高级别卵巢癌、输卵管癌或原发性腹膜癌患者的单药维持治疗。该批准基于FLAMES III期研究结果,显示塞帕拉比组中位无进展生存期为38.7个月,而安慰剂组为13.6个月。
原文明确给出批准事项与适用范围,读者可据此判断对同类产品的影响。
New maintenance option after first-line chemotherapy
The European Commission has approved Sepalna (senaparib) as a monotherapy maintenance treatment for adults with advanced epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer whose disease has responded either completely or partially following first-line platinum-based chemotherapy.
The approval covers patients with FIGO stage 3 and 4 disease and follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in September 2026. The decision, granted on 12 November 2026, marks a significant regulatory milestone for the treatment in Europe.
Pharmanovia and IMPACT Therapeutics announced the authorisation, which applies across the European Union. Pharmanovia holds exclusive regional development and commercialisation rights for senaparib across 66 countries, including the UK, Norway, Iceland, Switzerland, Liechtenstein, Australia, New Zealand and countries in the Middle East and North Africa.
Senaparib, developed by IMPACT Therapeutics, is a targeted anti-cancer therapy. The approval was supported by evidence from the phase 3 FLAMES study, a randomised, double-blind, placebo-controlled trial involving patients with newly diagnosed advanced ovarian cancer responding to first-line platinum-based chemotherapy, regardless of BRCA mutation status.
At a median follow-up of 48.5 months, the study showed median progression-free survival of 38.7 months in patients receiving senaparib compared with 13.6 months in the placebo group. Benefits were observed in both BRCA-mutated and BRCA wild-type patient populations.
Updated safety data from 403 patients showed that 5.6% of those treated with senaparib discontinued treatment because of treatment-emergent adverse events. The most common adverse events included anaemia, neutropenia, leukopenia, thrombocytopenia, increased transaminases, weight gain, nausea and abdominal pain.
No treatment-emergent adverse events resulted in death.
Stephan Eder, Chief Executive Officer of Pharmanovia, said: “The European Commission’s approval of Sepalna represents an important milestone for patients with advanced ovarian cancer and for our growing oncology portfolio.”
He added: “We congratulate our partner IMPACT Therapeutics on this significant achievement, reflecting years of dedicated research and clinical development.”
Eder continued: “Our focus at Pharmanovia is now on preparing for the introduction of Sepalna across Europe and working towards making this treatment available to eligible patients.”
来源:PharmaTimes · pharmatimes.com